These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25356603)

  • 1. One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.
    Signorovitch JE; Betts KA; Reichmann WM; Thomason D; Galebach P; Wu EQ; Chen L; DeAngelo DJ
    Curr Med Res Opin; 2015 Feb; 31(2):315-22. PubMed ID: 25356603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.
    Signorovitch JE; Wu EQ; Betts KA; Parikh K; Kantor E; Guo A; Bollu VK; Williams D; Wei LJ; DeAngelo DJ
    Curr Med Res Opin; 2011 Jun; 27(6):1263-71. PubMed ID: 21524239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
    Signorovitch J; Ayyagari R; Reichmann WM; Wu EQ; Chen L
    Cancer Treat Rev; 2014 Mar; 40(2):285-92. PubMed ID: 24112812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
    Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
    Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
    Takahashi K; Kantarjian HM; Yang Y; Sasaki K; Jain P; DellaSala S; Ravandi F; Kadia T; Pemmaraju N; Daver N; Borthakur G; Garcia-Manero G; Jabbour E; Cortes JE
    Cancer; 2016 Nov; 122(21):3336-3343. PubMed ID: 27509035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
    Erba HP; Pham DC; Zaiden R; Vu H; Tai S
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
    Giles FJ; Abruzzese E; Rosti G; Kim DW; Bhatia R; Bosly A; Goldberg S; Kam GL; Jagasia M; Mendrek W; Fischer T; Facon T; Dünzinger U; Marin D; Mueller MC; Shou Y; Gallagher NJ; Larson RA; Mahon FX; Baccarani M; Cortes J; Kantarjian HM
    Leukemia; 2010 Jul; 24(7):1299-301. PubMed ID: 20520639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
    Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
    Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.
    Iriyama N; Sugimoto KJ; Sato E; Takaku T; Tokuhira M; Nakazato T; Ishikawa M; Fujita H; Fujioka I; Kimura Y; Asou N; Kizaki M; Komatsu N; Hatta Y; Kawaguchi T
    Med Oncol; 2018 Sep; 35(11):142. PubMed ID: 30194496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
    Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
    Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
    Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
    Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
    Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
    Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.
    Cortes JE; Muresan B; Mamolo C; Cappelleri JC; Crescenzo RJ; Su Y; Gambacorti-Passerini C; Heeg B; Douglas Smith B
    Curr Med Res Opin; 2019 Sep; 35(9):1615-1622. PubMed ID: 30964361
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
    Sasaki K; Lahoti A; Jabbour E; Jain P; Pierce S; Borthakur G; Daver N; Kadia T; Pemmaraju N; Ferrajoli A; O'Brien S; Kantarjian H; Cortes J
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):152-62. PubMed ID: 26796981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
    Zhang X; Xu N; Yang Y; Lin H; Liu B; Du X; Liu X; Liang R; Chen C; Huang J; Zhu H; Pan L; Wang X; Li G; Liu Z; Zhang Y; Liu Z; Hu J; Liu C; Li F; Yang W; Meng L; Han Y; Lin L; Zhao Z; Tu C; Zheng C; Bai Y; Zhou Z; Chen S; Qiu H; Yang L; Sun X; Sun H; Zhou L; Liu Z; Wang D; Guo J; Pang L; Zeng Q; Suo X; Zhang W; Zheng Y; Zhang Y; Li W; Jiang Q
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e257-e266. PubMed ID: 38461040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.